Home » Stocks » Subversive Investor Relations

Subversive Investor Relations

Careful about what you read and perhaps believe. The editorial persona of Financial Skeptic is to be skeptical. simple business model. I climb the wall of worry. The other day I receive the following emails. Investors need to know that some of the opinions out there are bought and paid for. I leave the reader to follow the subversive logic. This blogger is not interested.


Thanks for the quick response.

We are working with Immunocellular Therapeutics (OTC BB: IMUC) to find qualified research candidates. We are looking for 8 original posts (200 – 300 words each), published on your site, over a 90 day period.

Disclosure, indicating that this is paid, but independent research, would be included with each post. Something along the lines of, “This is part of a paid, but independent research series on Immunocellular Therapeutics [link to all articles in the series]. The views and opinions expressed in this Series are purely my own. I do not own any Immunocellular Therapeutics Securities.”

There is no hard and fast rule regarding compensation, but it is based primarily on your distribution and reach. We have a budget of $800 – $2400 (and potentially more) for the Series. Payment would be made in two trenches.

Could you please provide some details regarding your site traffic, email distribution, etc.? Do you have any minimum compensation requirements? Once this information is gathered, I will consult with the company and get back to you shortly.

Thanks again for your response. I look forward to collaborating on this and future projects.

Best, Doug.

On Tue, Jan 11, 2011 at 1:34 PM, George Gutowski <georgegutowskiebox@hotmail.com> wrote:

Hi Doug
I would like to get more information on this opportunity



Date: Mon, 10 Jan 2011 17:44:41 -0500
Subject: Research Coverage

From: dcress@jsdcllc.com
To: dcress@jsdcllc.com

My name is Doug Cress. Apologies if this email reaches you in error.

We are looking to hire an analyst to initiate paid, but independent, research on an emerging biotech company.

The research would consist of +/- 8 blog posts over the course of 90 days (with full disclosure).

Please let me know if this opportunity is of interest and I will follow up with additional details.

Best regards,


Doug Cress